Copyright 2009 Medical News Today Latest Eczema / Psoriasis News From Medical News Today. http://www.medicalnewstoday.com/sections/eczema-psoriasis/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Mon, 23 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/171828.php http://www.medicalnewstoday.com/articles/171828.php Scientists of Helmholtz Zentrum München and the Center of Allergy and Environment (ZAUM) of Technische Universität München have discovered a new type of immune cells - the Th22 cells - which can protect the body against inflammation and aid in tissue repair. In the current online issue of the Journal of Clinical Investigation, Dr. Stefanie Eyerich and Dr. Eczema / Psoriasis Thu, 19 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/171389.php http://www.medicalnewstoday.com/articles/171389.php A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time this week in the Journal of Clinical Investigation. Immune System / Vaccines Wed, 18 Nov 2009 09:00:00 PST http://www.medicalnewstoday.com/articles/171358.php http://www.medicalnewstoday.com/articles/171358.php Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has obtained regulatory approval from Health Canada. "We are delighted that Health Canada has approved the use of Toctino for patients with severe chronic hand eczema unresponsive to potent topical steroids. Eczema / Psoriasis Wed, 18 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/171221.php http://www.medicalnewstoday.com/articles/171221.php Beginning Thursday, Nov. 19, 2009, the International Psoriasis Council (IPC) will host its second symposium at Baylor University Medical Center in Dallas. The two-day conference brings together dermatologists from Asia, Eastern Europe and Spain to elevate the global understanding of psoriasis and its treatment. Sessions will be facilitated by leading dermatologists and nurses dedicated to psoriasis management and research. Eczema / Psoriasis Mon, 02 Nov 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/169488.php http://www.medicalnewstoday.com/articles/169488.php A first-of-its-kind symposium has convened today that brings together U.S. and Latin American dermatologists in an effort to elevate the global understanding of psoriasis and its treatment. Presented by the International Psoriasis Council (IPC), the symposium will be held at the Baylor University Medical Center in Dallas this week and will include sessions led by leading dermatologists and nurses involved in psoriasis management and research. Eczema / Psoriasis Thu, 29 Oct 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/169078.php http://www.medicalnewstoday.com/articles/169078.php Findings from a national survey Psoriasis Uncovered, show that for those with the most severe1 form of the condition, psoriasis has an irreversible effect on one in two patients' lives. Eczema / Psoriasis Wed, 28 Oct 2009 20:00:00 PST http://www.medicalnewstoday.com/articles/169029.php http://www.medicalnewstoday.com/articles/169029.php PhotoMedex, Inc. (Nasdaq: PHMD) a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009. Eczema / Psoriasis Tue, 27 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168728.php http://www.medicalnewstoday.com/articles/168728.php Anal itching, also known as itchy bottom, pruritus ani or anusitis, is irritation and sometimes inflammation of the anus - located at the exit of the rectum. Itching severity varies and is usually exacerbated by such factors as type of clothing worn, whether the patient is seated or upright, moisture levels, pressure and general rubbing of the anal area. Dermatology Mon, 26 Oct 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/168674.php http://www.medicalnewstoday.com/articles/168674.php Millions of children in the United States between the ages of 1 and 11 may suffer from suboptimal levels of vitamin D, according to a large nationally representative study published in the November issue of Pediatrics, accompanied by an editorial. The study, led by Jonathan Mansbach, MD, at Children's Hospital Boston, is the most up-to-date analysis of vitamin D levels in U.S. children. Nutrition / Diet Fri, 23 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/168384.php http://www.medicalnewstoday.com/articles/168384.php Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy also known as phototherapy. Eczema / Psoriasis Sat, 17 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/167697.php http://www.medicalnewstoday.com/articles/167697.php Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection. But the molecular and cellular processes triggering these inflammatory and immune responses remain little understood. Immune System / Vaccines Thu, 15 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/167383.php http://www.medicalnewstoday.com/articles/167383.php Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009. Eczema / Psoriasis Thu, 01 Oct 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/165893.php http://www.medicalnewstoday.com/articles/165893.php Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety. Eczema / Psoriasis Mon, 28 Sep 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/165415.php http://www.medicalnewstoday.com/articles/165415.php The U.S. Food and Drug Administration approved Stelara (ustekinumab), a biologic product for adults who have a moderate to severe form of psoriasis. Plaque psoriasis is an immune system disorder that results in the rapid overproduction of skin cells. About 6 million people in the United States have plaque psoriasis which is characterized by thickened patches of inflamed, red skin, often covered with silvery scales. Eczema / Psoriasis Wed, 23 Sep 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/164805.php http://www.medicalnewstoday.com/articles/164805.php Incyte Corporation (Nasdaq:INCY) announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis. These results were obtained from a multi-center three-month Phase IIb trial comparing three once-daily doses of topical INCB18424 to vehicle in 200 patients with mild-to-moderate psoriasis. Eczema / Psoriasis Tue, 22 Sep 2009 06:00:00 PST http://www.medicalnewstoday.com/articles/164770.php http://www.medicalnewstoday.com/articles/164770.php Asthma, nasal symptoms and eczema is a major public health problem in Sweden, not least among young people. Half of all teenagers are affected in Västra Götaland County in West Sweden. This is shown in a study conducted in 2008 by the Sahlgrenska Academy at the University of Gothenburg, on the request of the Public Health Committee, Region Västra Götaland. The study also shows that the prevalence of allergies among young people has increased by ten percentage points since the year 2000. Allergy Wed, 16 Sep 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/164005.php http://www.medicalnewstoday.com/articles/164005.php The first genetic test for Psoriatic arthritis (PsA) is being launched today by PsoriasisDX, LLC, a subsidiary of molecular dermatology research and development innovator PharmaGenoma, Inc. PsA is a progressive irreversible joint disease associated with psoriasis. It is estimated that 20% to 40% of psoriasis patients will eventually develop PsA. Eczema / Psoriasis Sun, 13 Sep 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/163742.php http://www.medicalnewstoday.com/articles/163742.php Enbrel (etanercept), Wyeth's biological treatment for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis, is now available as a new easy-to-use pre-filled auto-injector device, known as the Enbrel MYCLIC pen. The Enbrel MYCLIC pen is a single-use auto-injector, designed to deliver Enbrel as a 50mg subcutaneous injection. It has been developed to offer ease-of-use and enhance patient confidence with the injection process. Arthritis / Rheumatology Thu, 10 Sep 2009 14:00:00 PST http://www.medicalnewstoday.com/articles/163518.php http://www.medicalnewstoday.com/articles/163518.php PSA is supporting the release of a new Eczema management resource - Eczema Management Guide For The Pharmacist during National Eczema Awareness Week which runs until 13 September. Eczema is a skin condition which affects about one in three Australians at some time in their lives. It usually starts when a child is a baby and is sometimes gone by the time the child is about six. Eczema / Psoriasis Thu, 10 Sep 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/163407.php http://www.medicalnewstoday.com/articles/163407.php Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today that its 75-patient Phase II clinical study with CF101 to treat patients with moderate to severe Psoriasis has successfully met its primary objectives. Patients in this double-blind study were randomly assigned to 1, 2 or 4 mg of CF101 or placebo twice daily. The drug was taken orally as a monotherapy for 12 weeks. Eczema / Psoriasis Mon, 31 Aug 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/162214.php http://www.medicalnewstoday.com/articles/162214.php The National Institute for Health and Clinical Excellence (NICE) has today published final guidance recommending the use of alitretinoin as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids. In these cases, alitretinoin is recommended, within its licensed indication, if the person is assessed as having severe disease. Treatment should stop as soon as an adequate response (hands clear or almost clear) has been achieved. Eczema / Psoriasis Mon, 31 Aug 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/162244.php http://www.medicalnewstoday.com/articles/162244.php People with psoriasis - an often distressing dermatological condition that causes lesions and red scaly patches on the skin - are less likely to react to looks of disgust by others than people without the condition, new research has found. University of Manchester scientists used magnetic resonance imaging (MRI) scans to compare the brains of 26 men, half of whom had chronic psoriasis. Eczema / Psoriasis Wed, 26 Aug 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/161896.php http://www.medicalnewstoday.com/articles/161896.php Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that the National Institute for Health and Clinical Excellence (NICE) issued its final guidance recommending the use of Toctino® (alitretinoin) within its licensed indication, as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids. Eczema / Psoriasis Thu, 20 Aug 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/161204.php http://www.medicalnewstoday.com/articles/161204.php Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, has added Mount Sinai School of Medicine as its second and final site for its expanded Phase 2 clinical trial of the Company's lead dermatology agent PH-10 for psoriasis. Jason Emer, M.D. Eczema / Psoriasis Wed, 05 Aug 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/159811.php http://www.medicalnewstoday.com/articles/159811.php Eczema is a chronic skin disorder characterized by dry, itchy, scaly skin and rashes. It is commonly known as "the itch that rashes." (1) While the exact cause of eczema is not known, it appears to result from a complex interaction of factors including personal and family genetics, immune response and environmental factors. (2) Scratching the affected area can lead to more itch, redness, swelling, scaling, cracking, oozing clear fluid and, ultimately, crusting. Eczema / Psoriasis